Penetration mechanisms of cold atmospheric plasma through biliary and pancreatic tissues for digestive cancer treatment


Emérick BIAFFEU NEMATCHOUA^a, Manon SOULIER^a, Bouchra LEKBABY^b, Marion JANONA^b, Laura FOUASSIER^b and Thierry DUFOUR^a

aLPP, Sorbonne Université, CNRS, Ecole Polytechnique, Paris, France

bSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France

NON-INVASIVE SURGICAL PLATFORM FOR BILIARY AND PANCREATIC CANCER

Poor prognosis cancers









Late diagnosis: asymptomatic cancers in early stages Treatments:

- Damaging healthy cells
- Depending on patient eligibility
- Not locoregional





- Develop a minimally invasive cold atmospheric plasma (CAP) delivery platform to precisely target digestive tract tumors.
- Enable personalized treatment by integrating patient diagnostics with in silico modeling to control plasma therapy.


Antitumor response of cold plasma on BTC

Demonstrate therapeutic efficacy and safety via in vitro and in vivo animal experiments.

DECIPHERING THE PHYSICO-CHEMICAL AND BIOLOGICAL MECHANISMS INDUCING ANTITUMOR RESPONSE

72 h post-treatment

Cold atmospheric plasma (CAP) alternative




Antitumoral action:

- Oxidative stress
- Immune system activation
- Cell death

Cell viability (2 min) 2000 (EU 1500

Applied voltage (kV)




Judée et al. (J. Phys. D: Appl. Phys., 2019)

Tumor growth


<u>INVESTIGATING MOUSE SKIN TISSUE AS A BARRIER TO REACTIVE SPECIES DIFFUSION</u>

Experimental setup Post-mortem skins of albino mice (C57BL/6j-Tyr c) Skin thickness: 450 μm Plasma treatment time: 2 min Controls Culture medium 1700 μL 25°C Negative Positive PTM test Tissue test





The results indicate that, under the tested conditions (2 minutes, 5 kV and 9 kV CAP), these species do not effectively cross murine skin, suggesting a significant limitation to passive diffusion.

The biological temperature threshold (40°C) is exceeded at the 9 kV voltage, which makes this experimental condition unsuitable for living preclinical models. In contrast, this threshold is not reached at 5 kV. Moreover, no macroscopic adverse effects are observed on the skin.



Macroscopic observation of skin samples





PERSPECTIVES

- Optimizing key plasma parameters (applied voltage and exposure time) to maximize therapeutic efficacy while minimizing unintended tissue damage
- Refining plasma delivery strategies
- Exploring other mechanisms of action such as electric field effects, and assess the long-term biological impact of CAP treatment















